The U.S. government is relinquishing control over supplies of remdesivir, the Covid-19 drug made by Gilead Sciences Inc. that had been in shortage since it was authorized for emergency use in May.
Starting Thursday, Gilead will sell the drug directly to hospitals in the same way it does other medicines based on market demand, the Department of Health and Human Services and the company said.
Gilead also said it is now able to meet current and future U.S. demand for remdesivir, which is sold under the brand-name Veklury, even in a potential worst-case scenario where there are large spikes in cases in the fall.
“We are in a position now that we will have sufficient supply of Veklury in the U.S. to treat all eligible hospitalized patients,” said Johanna Mercier, Gilead’s chief commercial officer, in an interview.
Before Thursday, HHS was responsible for allocating Gilead’s supply of remdesivir among U.S. states and territories.